Rabies General introduction - World Health Organization
y Postexposure prophylaxis (PEP) if required: administration of rabies immunoglobulin in case of severe exposure (WHO category 3). y PEP to be applied as soon as possible – vaccines with a potency at least 2.5 IU per single immunizing intramuscular dose according to one of the following schedules: (Volume of 1 intramuscular dose after
Download Rabies General introduction - World Health Organization
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
Federal Response to COVID-19: Therapeutics Clinical ...
www.phe.govFeb 15, 2022 · Paxlovid™ is not authorized for pre-exposure or post -exposure prophylaxis for prevention of COVID-19 Not authorized for use longer than 5 consecutive days Paxlovid™ may only be prescribed for an individual patient by physicians, advanced practice registered